AVANZANITE-BIOSCIENCE
27.8.2024 07:01:26 CEST | Business Wire | Press release
Avanzanite Bioscience B.V., a commercial-stage specialty pharmaceutical company, focused on bringing novel medicines for rare diseases to market, announced today that the European Commission (EC) granted marketing authorisation of AKANTIOR® (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. The formal approval by the EC follows previously reported positive opinion of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) as well as subsequent positive recommendation of the EMA Committee for Orphan Medicinal Products (COMP). Following more than 16 years of research & development (R&D), AKANTIOR is the first and only authorised medicinal product for the treatment of AK globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240826744342/en/
Adam Plich, Founder & CEO of Avanzanite Bioscience (Photo: Business Wire)
“Our studies have shown that with AKANTIOR, when used as monotherapy with the treatment delivery protocol established for use in the trial, medical cure rates of over 85% can be achieved. As the first authorised drug, I expect this to become the standard of care for this severe disease,” stated John Dart, Principal Investigator of the pivotal phase III ODAK trial, and Professor at the Moorfields Eye Hospital and the University College London Institute of Ophthalmology. “AKANTIOR can be expected to improve the cure rate without surgery, reducing both the high rates of morbidity – principally anxiety, pain, time off normal activities, time to cure – and blindness rates associated with current unlicensed, often compounded, combination therapies.”
In March 2024, results of the 135-patient, phase III, pivotal Orphan Drug for Acanthamoeba Keratitis (ODAK) trial, were published in Ophthalmology, demonstrating AKANTIOR’s absolute efficacy and safety. The trial showed that 84.8% of patients receiving AKANTIOR were cured. Furthermore, 66.7% of patients treated with AKANTIOR achieved full vision restoration with no patients resorting to optical cornea transplant. Only 7.5% of AKANTIOR-treated patients required a therapeutic cornea transplant.
“As an acanthamoeba keratitis (AK) Warrior, I am optimistic that AKANTIOR will have a significant and positive impact on AK patients,” commented Juliette Vila Sinclair Spence, a rare disease patient advocate and the Chairwoman and Founder of AK Eye Foundation – the first global foundation dedicated exclusively to this condition. “When I was diagnosed with AK, for me, there were no authorised drugs or standardised treatment protocols like AKANTIOR available. I had to rely on various compounded or off-label eye drops without a validated protocol. This approval has reignited my passion and commitment to increasing awareness about this rare eye disease.”
Acanthamoeba keratitis (AK) is a rare, severe, and progressive parasitic corneal infection caused by Acanthamoeba, a free-living amoeba. Urgent medical intervention is necessary as the disease leads to blindness and eye loss. AK often requires single or multiple cornea transplant procedures with comparably low graft survival rates. Patients report unbearable pain and extreme light sensitivity and can rarely work or lead normal lives until symptoms resolve, leaving patients with trauma for life. AK primarily affects contact lens wearers and is responsible for 50% of blindness cases in this demographic. In the absence of anti-amoebal treatment, 80.4% of patients require surgery, such as therapeutic cornea transplant, or eye removal in a historical cohort of 56 patients.
“No one fighting such a devastating rare disease should be left behind. This marketing authorisation is the beginning of a new chapter for the treatment of acanthamoeba keratitis (AK) and a monumental victory for AK patients in Europe,” stated Avanzanite’s Founder & CEO, Adam Plich. “We are grateful to our R&D partners at SIFI, the healthcare professionals, as well as the patients and their families who participated in the trials, for the years of dedication and hard work that made this day possible.”
To date, AKANTIOR has been provided to more than 200 patients across 12 countries through a pre-authorisation distribution program. “At Avanzanite, we are committed to supporting broad access to our innovative therapies and look forward to collaborating with local health authorities in 26 European countries to secure sustainable access agreements so we can save the eyes of as many eligible patients as possible,” Plich concluded.
Avanzanite secured exclusive rights to commercialise AKANTIOR in 26 countries across the European Economic Area and Switzerland through a license and supply agreement with SIFI, a leading international ophthalmic company headquartered in Italy. AKANTIOR is the second rare disease medicine commercialised by Avanzanite, expanding both the company’s portfolio and geographical footprint, in support of the ambition to become a global rare disease company.
ABOUT AKANTIOR®: AKANTIOR (polihexanide) is the first European Commission-approved medicinal product for AK. It is an anti-amoebic polymer granted Orphan Drug Designation (ODD) by the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA"). It acts on both the trophozoites and cysts of the protozoan Acanthamoeba. It is formulated at a unique high 0.8 mg/ml (0.08%) dose strength administered through a validated and standardised, day-only protocol as monotherapy eye drops in single-dose containers. Polihexanide is also being developed for the treatment of fungal keratitis for which it has ODD from both FDA and EMA.
ABOUT AVANZANITE BIOSCIENCE: We believe all patients should benefit from novel orphan or niche medicines regardless of where they live. Our vision is that no one is left behind when facing a debilitating rare disease. We also believe the people who have dedicated their careers to the research & development of novel orphan or niche medicines, deserve to witness how their tremendous efforts impact patients’ lives – the work of these heroes should not lie in vain. We make this happen by acquiring, licensing, or distributing approved or late-stage medicines for rare diseases, unlocking their potential, and commercialising them even where nobody else will. Founded in 2022, Avanzanite is headquartered in Amsterdam, the Netherlands, with commercial infrastructure and technical operations across Europe. Visit www.avanzanite.com for additional information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826744342/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release
ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa
Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release
Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the
Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release
Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said
Ant International’s Alipay+ and The New York Liberty Celebrate Season of Sustainability Impact on Community, Environmental and Youth Empowerment16.11.2026 05:08:00 CET | Press release
The first-season partnership delivers tangible results: 219 trees planted, 650 pairs of shoes donated, and youth empowered through inaugural Math Hoops tournament Ant International’s Alipay+, a leading cross-border fintech services platform, and the WNBA’s New York Liberty, today announced the results of their joint sustainability initiatives for the season. Marking the first season of the multi-year collaboration, Alipay+ and the New York Liberty planted a total of 219 trees — one for every three-pointer made by the New York Liberty and Alipay+ in-game fan contestants during home games at Barclays Center this season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115082353/en/ Students celebrate during the inaugural Liberty NBA Math Hoops Regional Tournament. In addition to the on-court tree-planting pledge, the partners concluded their fan-driven Sneaker Drive, collecting 650 pairs of shoes to support environmental cons
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
